NATURA-BISSÉ
22.11.2023 10:01:38 CET | Business Wire | Press release
Natura Bissé & Arch Amenities Group Europe have announced a formal collaboration to increase their collective presence in the luxury spa sector across the EU and the United Kingdom. The agreement fosters strategic and complementary growth opportunities for both brands, which will reference each other, capitalizing on the well-established reputation of the Natura Bissé brand, its professional and retail skincare products and services and Arch Amenities Group’s experience in managing and operating pre-eminent luxury wellness centers and spas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231122952800/en/
Barry Goldstein, CEO Arch Amenities Group (Photo: Natura Bissé)
The Spanish skincare firm, Natura Bissé, currently has a presence in more than 450 spa hotels around the world—35% of which are located in Europe—and is set to close the year with a total revenue of 100 million euros. With its headquarters in Barcelona, 82% of the company’s sales are recorded abroad, with the Unites States and China being its primary markets, followed by Spain. Over the next 3 years, Europe will become the company’s strategic focus with the aim of doubling its multi-channel presence in this region.
For its part, Arch Amenities Group and its 3800 employees currently manage over 430 properties around the world. Private clubs, fitness centers, commercial and residential spaces and, of course, hotels place their trust in the Group’s extensive experience. Among the hotel groups in their portfolio of clients are big names like Waldorf Astoria, Four Seasons and The Ritz-Carlton, who are also partners of Natura Bissé across the world.
Natura Bissé has been part of Arch Amenities Group’s Preferred Vendor Program since early 2023, connecting the Natura Bissé product suite to a host of renowned U.S.-based spas and wellness spaces such as the Eden Roc Miami Beach Resort or the Waldorf Astoria Washington DC.
Today this partnership adopts a new character as a “non-exclusive strategic agreement” in Europe, at a time when the hospitality sector is seeing increased demand for elevated wellness experiences. Proof of this comes from data in a recent report from the Global Wellness Institute, which highlights consistent 12% annual growth in the wellbeing market since 2020 and forecasts a further 52% growth by 2027.
“This strategic agreement represents a step-change in the way both leading brands address the changing needs of the European market and reinforces our collective commitment to offer unlimited innovation, inspiration as a pillar of growth and bespoke agile solutions. That is why I’m convinced that our collaboration with Arch Amenities Group Europe will allow us to expand our presence in first-class spas and wellbeing centers,” says Verónica Fisas, CEO at Natura Bissé Group.
“Partnering with Natura Bissé in Europe to develop spas is an ideal fit for Arch as we grow our presence in Europe. As one of the most celebrated luxury skincare brands in the world, our strategic collaboration with Natura Bissé allows us to extend our proven expertise in developing and managing luxury wellness spaces to bring guests an unparalleled experience powered by great products, outstanding hospitality and elevated service,” says Barry Goldstein, CEO at Arch Amenities Group.
ABOUT ARCH AMENITIES GROUP
Arch Amenities Group, based in Rockville, Maryland, is a leading provider of hospitality management and consulting services for commercial and residential properties, hotels, spas and private clubs and recreation spaces worldwide. Arch provides daily management services as well as feasibility studies, planning and design consultancy as well as recruiting, pre-opening and sustaining strategy and support. Arch is a portfolio company of private equity firm CI Capital Partners.
ABOUT NATURA BISSÉ
Natura Bissé is a globally renowned luxury skincare company. Founded in Barcelona in 1979, Natura Bissé fuses pioneering technology with the most delicate human touch in order to listen and adapt to the differing needs of each and every client.
The constant pursuit of excellence has earned Natura Bissé numerous awards, notably recognition for being the “World’s Best Spa Brand” for four consecutive years (2018-2021).
With presence in 40 countries, Natura Bissé continues to expand around the world throughout the most distinguished luxury retailers and best-in-class spas.
In 2008 the brand helped establish the Ricardo Fisas Natura Bissé Foundation to contribute to the well-being of people in vulnerable situations. To support the Foundation’s initiatives, Natura Bissé has three fundraising lines of hotel toiletries.
Images available here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231122952800/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
